Viewing Study NCT05832827


Ignite Creation Date: 2025-12-25 @ 5:11 AM
Ignite Modification Date: 2025-12-26 @ 4:17 AM
Study NCT ID: NCT05832827
Status: RECRUITING
Last Update Posted: 2023-10-23
First Post: 2023-04-16
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)
Sponsor: National Cancer Center, Japan
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module